Dr. Adelaiye-Ogala’s research program investigates the mechanistic determinants underlying treatment resistance in genitourinary cancers and develops optimal therapeutic strategies to achieve durable clinical outcomes. Her research group engages in basic and translational research in genitourinary cancers, emphasizing the molecular regulation of signaling pathways in prostate and kidney cancers and therapeutic strategies to overcome drug resistance driven by genetic and epigenetic mechanisms. The laboratory is equipped with expertise in advanced multi-omics assays, drug screening protocols, and developing and maintaining patient-derived xenograft models to assess the efficacy of novel pipeline agents within three-dimensional organoid cultures and animal models.
Three significant projects in my lab include (i) targeting drivers of androgen receptor (AR) cistrome reprogramming associated with advanced aggressive prostate cancer, (ii) investigating post-translational modulations and dynamics of pro-oncogenic glucocorticoid receptor activity as a compensatory hormone nuclear receptor in prostate cancers that have developed resistance to FDA-approved standard care, and (iii) developing and characterizing patient-derived xenograft (PDX) and organoid models of prostate cancers, specifically from underrepresented populations.